第一三共
Daiichi Sankyo (China) develops and sells prescription medicines in China, serving healthcare professionals, medical institutions, and patients across oncology, cardiovascular, anti-infective, respiratory, and pain-management needs, with a core focus on precision-targeted antibody-drug conjugate oncology therapies.
- Company typePrivate
- Founded1998
- HeadquartersShanghai, China
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What 第一三共 does
Daiichi Sankyo (China) Holdings Co., Ltd. (第一三共（中国）投资有限公司) is the wholly owned China subsidiary of Japan-based Daiichi Sankyo Co., Ltd. (第一三共株式会社), a Tokyo Stock Exchange-listed company (Ticker: 4568). It officially entered China in 1998 after a market relationship that began in the 1980s, operates with 501–1,000 employees, and serves healthcare professionals, medical institutions, and patients with prescription medicines spanning oncology, cardiovascular, anti-infective, respiratory, and pain-management needs.
The company maintains a China value chain covering research and development, manufacturing, and sales. Its portfolio is organized into oncology, basic treatment, and healthcare categories; oncology includes precision-targeted antibody-drug conjugate medicines, while basic treatment covers cardiovascular, anti-infective, respiratory, and pain-management therapies. Daiichi Sankyo also operates the DS Medical Family Platform (DS 医家平台) for healthcare-professional product information and resources. Its revenue comes from pharmaceutical product sales through direct healthcare-professional and medical-institution channels, with products also sold through pharmacies; product pricing is not publicly disclosed.
第一三共 firmographics
Firmographics- Name
- 第一三共
- Legal name
- 第一三共（中国）投资有限公司
- Website
- https://daiichisankyo.com.cn
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Daiichi Sankyo (China) develops and sells prescription medicines in China, serving healthcare professionals, medical institutions, and patients across oncology, cardiovascular, anti-infective, respiratory, and pain-management needs, with a core focus on precision-targeted antibody-drug conjugate oncology therapies.
- Ownership category
- akta.pro rank
第一三共 industry classification
Industry- Product category
- Prescription Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where 第一三共 is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Offices7 records
Markets served
第一三共 business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Pharmaceutical Product Sales: 第一三共 generates revenue through the sale of innovative pharmaceutical products including oncology drugs, cardiovascular medications, anti-infectives, respiratory treatments, and pain management solutions. Products are distributed through healthcare professional channels and medical institutions in China.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
第一三共 product offering
Product offeringCore offering
Daiichi Sankyo China develops, manufactures, and sells innovative prescription pharmaceuticals in Mainland China across five therapeutic areas: oncology, cardiovascular, anti-infection, respiratory, and pain management. The company maintains a full in-country value chain from R&D to manufacturing (Shanghai facility) to a direct sales force reaching medical institutions and licensed healthcare professionals, with an emphasis on precision-targeted ADC (antibody-drug conjugate) oncology medicines sourced from its Japanese parent.
Product overview
第一三共 is a global pharmaceutical company with over 120 years of history that offers a portfolio of prescription medications across three main therapeutic areas: Oncology (tumor treatment including ADC-based precision medicines), Basic Treatment (cardiovascular, anti-infection, respiratory, and pain management), and Healthcare products. The company operates through its China subsidiary and provides products in key treatment areas including oncology, cardiovascular, anti-infection, respiratory, and analgesia. A digital platform called DS医家平台 serves healthcare professionals. The company focuses on antibody drug conjugate (ADC) technology for cancer treatment and maintains a full value chain from R&D to manufacturing to sales in China.
Differentiator
Problem solved
Functional benefit
Products and services
- Oncology therapeutics (肿瘤领域) Portfolio of prescription cancer medicines, including precision-targeted Antibody-Drug Conjugate (ADC) drugs, for Chinese oncology patients treated by hospital-based prescribers.
- Basic Treatment therapeutics (基础治疗) Portfolio of prescription medicines covering cardiovascular, anti-infection, respiratory, and pain management indications for Chinese patients, developed using the parent group's innovative drug-discovery and delivery methods.
- Healthcare and wellness products (医药保健) Healthcare and wellness product line offering health management solutions to Chinese consumers within the Daiichi Sankyo China portfolio.
Companies that use 第一三共
Customer profileSegments2 records
Ideal customer profiles1 record
第一三共 technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
第一三共 partnerships and signals
Strategic signalScale indicators3 records
Recent moves4 records
Expansion highlights3 records
第一三共 competitors and assessment
Company assessmentDirect peers
- Novartis (China): Innovative pharma major with China operations spanning oncology, cardiovascular, and specialty care. Comparable as a branded-innovator peer competing for the same NRDL slots and HCP mindshare.
- Sanofi (China): Multinational pharma with diversified China portfolio across specialty care, cardiovascular, and anti-infectives. Comparable breadth of therapeutic areas and hospital-channel commercialization model.
- Takeda (China): Japanese pharma peer also operating through a China subsidiary structure with specialty/oncology and rare-disease focus. Comparable as a fellow Japan-headquartered multinational innovator operating in China via a similar subsidiary footprint.
- Roche (China): Oncology and specialty-care leader with a major China presence across innovative biologics and diagnostics. Comparable therapeutic mix (oncology dominance with cardiovascular/anti-infective adjacencies) and direct hospital sales model.
- AstraZeneca (China): Global pharma major with a deeply established China commercial footprint spanning oncology (including ADC collaboration with Daiichi Sankyo on Enhertu), cardiovascular, and respiratory. Highly comparable as a multinational innovator-pharma subsidiary competing in the same HCP and hospital channels.
- Pfizer (China): Diversified multinational pharma with oncology, cardiovascular, anti-infective, and pain-management franchises in China. Comparable portfolio breadth, scale of China field sales force, and exposure to NRDL dynamics.
- Bristol-Myers Squibb (China): Global oncology and cardiovascular-focused pharma with established China presence. Comparable given its heavy oncology/immuno-oncology mix and direct hospital sales motion in China.
- Eli Lilly (China): US-headquartered innovator pharma with growing China operations across oncology (Verzenio) and diabetes/cardiovascular. Comparable as a multinational branded-pharma competitor in the same hospital and HCP channels.
- Merck & Co. (MSD China): Global oncology powerhouse (Keytruda) with substantial China presence and hospital-channel oncology sales. Comparable given its oncology-led innovative pharma model and NRDL exposure.
- Bayer (China): Multinational pharma with China operations spanning cardiovascular, oncology, and specialty care. Comparable diversified innovative-pharma portfolio and direct-to-hospital go-to-market motion.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
第一三共 social profiles
Digital presence第一三共 financial estimates
Financial estimateRevenue estimate
Valuation estimate
第一三共 leadership team
Management profileNumber of profiles
第一三共 subsidiaries and ownership
Company hierarchySubsidiaries1 record
第一三共 funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
第一三共 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 第一三共
What does 第一三共 do?
Daiichi Sankyo China develops, manufactures, and sells innovative prescription pharmaceuticals in Mainland China across five therapeutic areas: oncology, cardiovascular, anti-infection, respiratory, and pain management. The company maintains a full in-country value chain from R&D to manufacturing (Shanghai facility) to a direct sales force reaching medical institutions and licensed healthcare professionals, with an emphasis on precision-targeted ADC (antibody-drug conjugate) oncology medicines sourced from its Japanese parent.
Is 第一三共 a public or private company?
第一三共 is a private company. It is classified as corporate owned and is currently operating.
When was 第一三共 founded?
第一三共 was founded in 1998. It employs 501 to 1,000 people.
Where is 第一三共 based?
第一三共 is headquartered in Shanghai, China, in the Asia region.
How does 第一三共 make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are 第一三共's main competitors?
Direct peers on record are Novartis (China), Sanofi (China), Takeda (China), Roche (China), AstraZeneca (China), Pfizer (China), Bristol-Myers Squibb (China), Eli Lilly (China), Merck & Co. (MSD China) and Bayer (China).
Does 第一三共 have an API?
No public API is recorded for 第一三共.
What industry is 第一三共 in?
第一三共's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 325412 and its SIC code is 2834.